A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved..
Cellular immune defects associated with suboptimal responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination in people receiving hemodialysis (HD) are poorly understood. We longitudinally analyze antibody, B cell, CD4+, and CD8+ T cell vaccine responses in 27 HD patients and 26 low-risk control individuals (CIs). The first two doses elicit weaker B cell and CD8+ T cell responses in HD than in CI, while CD4+ T cell responses are quantitatively similar. In HD, a third dose robustly boosts B cell responses, leads to convergent CD8+ T cell responses, and enhances comparatively more T helper (TH) immunity. Unsupervised clustering of single-cell features reveals phenotypic and functional shifts over time and between cohorts. The third dose attenuates some features of TH cells in HD (tumor necrosis factor alpha [TNFα]/interleukin [IL]-2 skewing), while others (CCR6, CXCR6, programmed cell death protein 1 [PD-1], and HLA-DR overexpression) persist. Therefore, a third vaccine dose is critical to achieving robust multifaceted immunity in hemodialysis patients, although some distinct TH characteristics endure.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Cell reports. Medicine - 4(2023), 3 vom: 21. März, Seite 100955 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
B cell immunity |
|---|
| Anmerkungen: |
Date Completed 24.03.2023 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xcrm.2023.100955 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353692719 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353692719 | ||
| 003 | DE-627 | ||
| 005 | 20231227131137.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2023.100955 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM353692719 | ||
| 035 | |a (NLM)36863335 | ||
| 035 | |a (PII)S2666-3791(23)00047-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sannier, Gérémy |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.03.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Cellular immune defects associated with suboptimal responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination in people receiving hemodialysis (HD) are poorly understood. We longitudinally analyze antibody, B cell, CD4+, and CD8+ T cell vaccine responses in 27 HD patients and 26 low-risk control individuals (CIs). The first two doses elicit weaker B cell and CD8+ T cell responses in HD than in CI, while CD4+ T cell responses are quantitatively similar. In HD, a third dose robustly boosts B cell responses, leads to convergent CD8+ T cell responses, and enhances comparatively more T helper (TH) immunity. Unsupervised clustering of single-cell features reveals phenotypic and functional shifts over time and between cohorts. The third dose attenuates some features of TH cells in HD (tumor necrosis factor alpha [TNFα]/interleukin [IL]-2 skewing), while others (CCR6, CXCR6, programmed cell death protein 1 [PD-1], and HLA-DR overexpression) persist. Therefore, a third vaccine dose is critical to achieving robust multifaceted immunity in hemodialysis patients, although some distinct TH characteristics endure | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a B cell immunity | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hemodialysis | |
| 650 | 4 | |a Immune cell phenotyping | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a T cell immunity | |
| 650 | 4 | |a Vaccine response | |
| 650 | 4 | |a mRNA vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Nicolas, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Dubé, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Marchitto, Lorie |e verfasserin |4 aut | |
| 700 | 1 | |a Nayrac, Manon |e verfasserin |4 aut | |
| 700 | 1 | |a Tastet, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Debashree |e verfasserin |4 aut | |
| 700 | 1 | |a Tauzin, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Lima-Barbosa, Raphaël |e verfasserin |4 aut | |
| 700 | 1 | |a Laporte, Mélanie |e verfasserin |4 aut | |
| 700 | 1 | |a Cloutier, Rose |e verfasserin |4 aut | |
| 700 | 1 | |a Sreng Flores, Alina M |e verfasserin |4 aut | |
| 700 | 1 | |a Boutin, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Shang Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Benlarbi, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Shilei |e verfasserin |4 aut | |
| 700 | 1 | |a Bourassa, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Gendron-Lepage, Gabrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Medjahed, Halima |e verfasserin |4 aut | |
| 700 | 1 | |a Goyette, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Brassard, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Delgado, Gloria-Gabrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Niessl, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Gokool, Laurie |e verfasserin |4 aut | |
| 700 | 1 | |a Morrisseau, Chantal |e verfasserin |4 aut | |
| 700 | 1 | |a Arlotto, Pascale |e verfasserin |4 aut | |
| 700 | 1 | |a Rios, Norka |e verfasserin |4 aut | |
| 700 | 1 | |a Tremblay, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Martel-Laferrière, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Prat, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Bélair, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Beaubien-Souligny, William |e verfasserin |4 aut | |
| 700 | 1 | |a Goupil, Rémi |e verfasserin |4 aut | |
| 700 | 1 | |a Nadeau-Fredette, Annie-Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Lamarche, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Finzi, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Suri, Rita S |e verfasserin |4 aut | |
| 700 | 1 | |a Kaufmann, Daniel E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 4(2023), 3 vom: 21. März, Seite 100955 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2023 |g number:3 |g day:21 |g month:03 |g pages:100955 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2023.100955 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2023 |e 3 |b 21 |c 03 |h 100955 | ||